Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
Intense microneedling with heavy pressure and bleeding did not improve hair growth after 4 months. The user advises against this method, noting no benefits and potential harm, and mentions using minoxidil without success.
The conversation discusses switching from oral to topical finasteride for hair loss, with concerns about application methods and side effects like dizziness and low energy. Users suggest mixing finasteride with minoxidil for better scalp coverage and dosage control.